2024
A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).
Henick B, Veluswamy R, Halmos B, Labbe K, Sender N, Sta Ana S, Chen L, Punekar S, Singh J, Lee M, Shu C, Herzberg B, Chin L, Velcheti V. A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI). Journal Of Clinical Oncology 2024, 42: tps1642-tps1642. DOI: 10.1200/jco.2024.42.16_suppl.tps1642.Peer-Reviewed Original ResearchNon-small cell lung cancerIncidence of immune-related adverse effectsImmune checkpoint inhibitorsRun-in phaseTreatment landscape of non-small cell lung cancerNon-small cell lung cancer patientsImmune checkpoint inhibitor useImmune-related adverse effectsDiagnosis of non-small cell lung cancerICI-treated patientsEarly treatment discontinuationMinority patientsCell lung cancerEarly-stage diseasePhase IV studyImprove treatment outcomesStandard of carePotential poor outcomesHealth literacy levelsReduce health disparitiesCheckpoint inhibitorsEthnic minority patientsEthnic/racial minority patientsTreatment discontinuationHealth care resources
2022
Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis.
Barbaro A, Siskin M, Grello C, Hernandez A, Dublin J, Breslin S, Punekar S, Velcheti V. Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2022, 40: e21120-e21120. DOI: 10.1200/jco.2022.40.16_suppl.e21120.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune related adverse eventsImmune checkpoint inhibitorsAdvanced non-small cell lung cancerSevere pneumonitisPD-L1Combination therapyCTLA-4Use of ICIsCombination immune checkpoint inhibitorsLife-threatening complicationsRelated adverse eventsCell lung cancerLung cancer patientsT cell populationsInverse variance weightingGrade pneumonitisCheckpoint inhibitorsInterventional armAdverse eventsCytotoxic chemotherapyImmune suppressionCancer patientsLung cancerClinical trials
2021
Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer
Punekar S, Castillo R, Sandigursky S, Cho D. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal Of Immunotherapy 2021, 44: 335-337. PMID: 34166301, DOI: 10.1097/cji.0000000000000380.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsAutoimmune conditionsDiscontinuation of ICIsPD-1/PD-L1Concurrent immune checkpoint inhibitorsImmune-related adverse eventsMetastatic renal cell carcinomaRole of IVIgUnderlying autoimmune conditionClasses of medicationsRenal cell carcinomaParaneoplastic dermatomyositisIntravenous immunoglobulinAdverse eventsPD-L1Antitumor responseCell carcinomaImmunomodulatory agentsMetastatic cancerImmune pathwaysExacerbationPatientsTreatmentCancerResponse to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma
Shah P, Punekar S, Pavlick A. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research 2021, 31: 242-248. PMID: 33741813, DOI: 10.1097/cmr.0000000000000730.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsProgression-free survivalHigh-grade immune-related adverse eventsImmune checkpoint inhibitorsOverall survivalDisease progressionAdverse eventsAdvanced melanomaInitial irAEImmune checkpoint inhibitor rechallengeImmune related adverse eventsMedian progression-free survivalUnresectable stage III melanomaMedian overall survivalPercent of patientsRelated adverse eventsStage III melanomaLimited clinical evidenceRisk-benefit profileContinuation of treatmentNYU Langone HealthICI initiationICI rechallengeICI therapyCheckpoint inhibitors